Showing results (71-80 of 95) with videos related to

Sort By:
Pageof 10
Oncotarget|November 7, 2015
Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysisPatrizia Vici, Anna Di Benedetto, Cristiana Ercolani, et al.
Oncotarget|September 19, 2015
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patientsBruno Vincenzi, Chiara Cremolini, Andrea Sartore-Bianchi, et al.
Breast Cancer Research and Treatment|September 20, 2014
Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER studyPatrizia Vici, Laura Pizzuti, Clara Natoli, et al.
BMC Cancer|November 12, 2017
Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter "real life" studyLuca Cindolo, Clara Natoli, Cosimo De Nunzio, et al.
Biomedical Reports|January 14, 2020
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The PRACTICE studyMelissa Bersanelli, Elisabetta Lattanzi, Nunziata D'Abbiero, et al.
Scientific Reports|September 8, 2017
Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt studyLaura Pizzuti, Paolo Marchetti, Clara Natoli, et al.
Tumori|February 18, 2015
Chemotherapy-induced nausea and vomiting in Italian cancer centers: results of CINVDAY, a prospective, multicenter studyMichele De Tursi, Consiglia Carella, Silverio Tomao, et al.
Journal of Cellular Physiology|July 16, 2017
Neoadjuvant chemotherapy in triple-negative breast cancer: A multicentric retrospective observational study in real-life settingTeresa Gamucci, Laura Pizzuti, Isabella Sperduti, et al.
Journal of Cellular Physiology|November 19, 2016
A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast CancerTeresa Gamucci, Lucia Mentuccia, Clara Natoli, et al.
Cancer Biology & Therapy|January 17, 2018
Body mass index in HER2-negative metastatic breast cancer treated with first-line paclitaxel and bevacizumabLaura Pizzuti, Domenico Sergi, Isabella Sperduti, et al.
Pageof 10